Article of the day, September 14th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Authors: Andrea J. Bullock, Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani S. Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou-Alfa, Neil H. Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin M. Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloe Delepine, Tyler J. Curiel, Justin Stebbing, Heinz-Josef Lenz, Steven J. O’Day and  Anthony B. El-Khoueiry.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.